Clinical Therapeutics/New Technology-Oral Agents

Clinical Therapeutics/New Technology-Oral Agents

You have access
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge Jabbour, Marcus Lind

Diabetes Care Aug 2019, 42 (8) 1464-1472; DOI: 10.2337/dc18-1988
You have access
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults
The RISE Consortium*

Diabetes Aug 2019, 68 (8) 1670-1680; DOI: 10.2337/db19-0299
You have access
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi, Yuksel Altuntas, Nebojsa M. Lalic, Enrique C. Morales Villegas, Ole K. Jeppesen, Erik Christiansen, Christin L. Hertz, Martin Haluzík

Diabetes Care Jul 2019, dc190749; DOI: 10.2337/dc19-0749
You have access
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Julio Rosenstock, Christopher H. Sorli, Michael E. Trautmann, Cristóbal Morales, Ulrich Wendisch, George Dailey, Marcus Hompesch, In Young Choi, Jahoon Kang, John Stewart, Kun-Ho Yoon

Diabetes Care Jul 2019, dc182648; DOI: 10.2337/dc18-2648
You have access
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Bruce A. Perkins, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, David Z. Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T. George, Jan Marquard, Nima Soleymanlou

Diabetes Care Jul 2019, dc190548; DOI: 10.2337/dc19-0548
You have access
Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program
Thomas Danne, Bertrand Cariou, John B. Buse, Satish K. Garg, Julio Rosenstock, Phillip Banks, Jake A. Kushner, Darren K. McGuire, Anne L. Peters, Sangeeta Sawhney, Paul Strumph

Diabetes Care May 2019, 42 (5) 919-930; DOI: 10.2337/dc18-2149
You have access
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K. Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson, Jan Oscarsson, Jarna C. Hannukainen, Pirjo Nuutila

Diabetes Care May 2019, 42 (5) 931-937; DOI: 10.2337/dc18-1569
You have access
Importance of Treatment Status in Links Between Type 2 Diabetes and Alzheimer’s Disease
Elissa C. McIntosh, Daniel A. Nation

Diabetes Care May 2019, 42 (5) 972-979; DOI: 10.2337/dc18-1399
You have access
Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride
Sven Kohler, Stefan Kaspers, Afshin Salsali, Cordula Zeller, Hans J. Woerle

Diabetes Care Aug 2018, 41 (8) 1809-1816; DOI: 10.2337/dc17-1525
Open Access
Sodium–Glucose Cotransporter 2 Inhibitors: A Case Study in Translational Research
Amber L. Beitelshees, Bruce R. Leslie, Simeon I. Taylor

Diabetes Jun 2019, 68 (6) 1109-1120; DOI: 10.2337/dbi18-0006

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Oral Agents

Pages

Navigate

More Information

Other ADA Resources